

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Abacus Health Products, Inc. (the "Issuer").

Trading Symbol: ABCS

Number of Outstanding Listed Securities: 11,999,473

Date: November 6, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Issuer Response: During the month of October, the Issuer has been focused on growing its operations and working to achieve product placement with new customers.

2. Provide a general overview and discussion of the activities of management.

Issuer Response: Please see item 1 above. Management has been actively involved in managing operations and seeking new customer opportunities.

Several meetings have taken place with pharmacy and grocery chains where the Issuer presented the product offering and discussed potential product placement. The Issuer attended the UNIFI winter buying show, GMDC Selfcare Summit, and National Community Pharmacists Association show.

The Issuer participated in the following investor conferences: Cannapreneur in Boston, IC3 in New York, and Benzinga in Chicago.

The Issuer also participated in several activation events where consumers were introduced to the CBDMEDIC brand and received product samples: Tough Mudder Norcal, Stadium Blitz Tampa and Buffalo, and two events at Gillette Stadium.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Issuer Response: No new products or services were developed during the month of October. The Issuer is actively presenting its new advanced skin care line which launched in February 2019. The new skin care line includes products for skin conditions such as acne, eczema, itch and rash. See item 2 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Issuer Response: None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Issuer Response: The Issuer entered into an agreement with Gillette Stadium and Patriot Place to promote the awareness of its CBDMEDIC brand. The three-tiered partnership includes elements of branding, activation, and hospitality for the 2019 and 2020 seasons. This partnership further enhances the recently announced relationship between three-time champion Rob Gronkowski and Abacus. A press conference was held on October 25, 2019 with Rob Gronkowski at Gillette Stadium announcing the agreement which garnered significant national media attention on television, radio, print, and on-line for CBDMEDIC.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Issuer Response: Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Issuer Response: Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Issuer Response: The Issuer continues to grow its customer base and acquire new customers such as pharmacies, grocery store chains, and health care practitioners. During the month the Issuer entered into a new distribution agreement with E&S International Enterprises for the distribution of CBDMEDIC products to the convenience store market as well as a major national retail pharmacy chain will begin offering three CBDMEDIC products.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Issuer Response: Not applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Issuer Response: The Issuer hired one employee during the month, a customer service supervisor. There were no terminations or lay-offs in the month and there are no anticipated lay-offs.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Issuer Response: Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Issuer Response: Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Issuer Response: Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Subordinate Voting Shares	72,373	Conversion by holders of proportionate voting shares of the Issuer into subordinate voting shares of the Issuer	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

Issuer Response: Not applicable.

16. Provide details of any changes in directors, officers or committee members.

Issuer Response: Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

Issuer Response: No new updates. See previous SEDAR filings.

Certificate Of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 6, 2019.

Henry R. Hague, III
Name of Director or Senior Officer

/s/ Henry R. Hague, III
Signature
CFO _____
Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer	End	October 2019	YY/MM/D
Abacus Health Products, Inc.			2019/11/06
Issuer Address			
10 Wanless Avenue, Suite 201			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
Toronto, ON M4N 1V6	()	(416) 848-1457	
Contact Name	Contact Position	Contact Telephone No.	
Hank Hague	CFO	(401) 347-2778	

Contact Email Address
investorrelations@abacushp.com

Web Site Address
www.abacushp.com